Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction

Exclusion Criteria

• •1. History of hypersensitivity or allergy to ACE inhibitors (ACEIs), ARBs, or NEP inhibitors
• •2. Known history of angioedema
• •3. Previous LVEF \< 40% at any time
• •4. Systolic blood pressure \< 100 mmHg or \> 180 mmHg
• •5. Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy)
• •6. Unstable angina, myocardial infarction, stroke, transient ischemic attack, or cardiovascular surgery or urgent percutaneous coronary intervention (PCI) within 3 months of screening or elective PCI within 30 days of entry
• •7. Significant valvular stenosis or regurgitation (greater than moderate in severity), hypertrophic, restrictive or obstructive cardiomyopathy including amyloidosis, constrictive pericarditis, primary pulmonary hypertension, or biopsy proven active myocarditis
• •8. Severe congenital heart disease
• •9. History of heart transplant or with LV assist device
• •10. Evidence of severe hepatic disease as determined by any one of the following: history of hepatic encephalopathy, history of esophageal varices, or history of porto-caval shunt.
• •11. Glomerular filtration rate \< 20 ml/min/1.73 m2 on most recent clinical laboratories\*
• •12. Serum potassium of \> 5.5 mEq/dL on most recent clinical laboratories\*
• •13. Concomitant use of aliskiren in patients with diabetes
• •14. Currently receiving an investigational drug
• •15. Inability to comply with planned study procedures
• •16. Female subject who is pregnant or breastfeeding
• •* Performed within 90 days of enrollment